Literature DB >> 12205413

Mechanism for the action of bone morphogenetic proteins and regulation of their activity.

Sohei Ebara1, Kohzo Nakayama.   

Abstract

Although the bone morphogenetic proteins (BMPs) are multifunctional proteins, implantation of osteogenic BMPs such as BMP-2 and BMP-7 at an osseous or extraosseous site results in bone and cartilage formation. These molecules are soluble, local-acting signaling proteins, which bind to specific receptors on the surface of the cell. The receptors then transduce the signal via a group of proteins called Smads, which in turn activate particular genes. In vivo, these BMPs act primarily as differentiation factors, turning responsive mesenchymal cells into cartilage- and bone-forming cells. A summary of the in vitro and in vivo studies suggests that implantation of these BMPs stimulates cells from the soft and hard tissues (e.g., muscle, bone marrow, periosteum) to become bone, and in some cases, cartilage forming cells. The activity of BMPs is tightly controlled at many levels. The tissue-specific transcription factor (basic helix-loop-helix factor) and its binding sequence (E-box) together play a critical role in deciding the expression of BMPs. Outside the cell, soluble inhibitory proteins such as noggin, chordin, and follistatin can bind certain of the BMPs and inhibit their binding to cell surface receptors. Inside the cell, the activity of BMPs is controlled through the combination of signal-transducing and inhibitory Smad proteins. Bone morphogenetic proteins can upregulate expression of the inhibitory Smad proteins. These Smads are phosphorylated and translocate into the nucleus, where they regulate the transcription of target genes together with other transcription factors including PEBP2alphaA/Cbfa1. Cooperation between PEBP2alphaA/Cbfa1 and BMP-activated Smad (Smad1/5) in the nucleus induces the expression of the genes related to the osteoblast phenotype. In addition, a number of negative regulators of BMP action exist within the nucleus. All of these regulatory mechanisms together cause the bone-induction process to be controlled tightly and self-limiting. Thus, bone induction is observed only locally at the site of BMP and matrix implantation, as defined by the volume of matrix, and it is limited temporally only to the time when the BMP is present.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12205413     DOI: 10.1097/00007632-200208151-00004

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  27 in total

Review 1.  Growth factor-eluting technologies for bone tissue engineering.

Authors:  Ethan Nyberg; Christina Holmes; Timothy Witham; Warren L Grayson
Journal:  Drug Deliv Transl Res       Date:  2016-04       Impact factor: 4.617

Review 2.  Bone graft substitutes for spine fusion: A brief review.

Authors:  Ashim Gupta; Nitin Kukkar; Kevin Sharif; Benjamin J Main; Christine E Albers; Saadiq F El-Amin Iii
Journal:  World J Orthop       Date:  2015-07-18

Review 3.  New Strategies in Enhancing Spinal Fusion.

Authors:  Yoshihiro Katsuura; Karim Shafi; Chelsie Jacques; Sohrab Virk; Sravisht Iyer; Matthew Cunningham
Journal:  HSS J       Date:  2020-02-02

4.  Long-term safety and efficacy of human bone morphogenetic protein (HBMP) in the treatment of resistant non-unions and failed arthrodesis.

Authors:  Arya Nick Shamie; Hamed Yazdanshenas; Eric Egan Johnson
Journal:  J Clin Orthop Trauma       Date:  2016-11-16

Review 5.  Bone-seeking agents for the treatment of bone disorders.

Authors:  Jacqueline Cawthray; Ellen Wasan; Kishor Wasan
Journal:  Drug Deliv Transl Res       Date:  2017-08       Impact factor: 4.617

6.  Influence of bone morphogenetic protein-2 on the extracellular matrix, material properties, and gene expression of long-term articular chondrocyte cultures: loss of chondrocyte stability.

Authors:  David A Krawczak; Jennifer J Westendorf; Cathy S Carlson; Jack L Lewis
Journal:  Tissue Eng Part A       Date:  2009-06       Impact factor: 3.845

Review 7.  Bone-Targeting Systems to Systemically Deliver Therapeutics to Bone Fractures for Accelerated Healing.

Authors:  Jeffery J Nielsen; Stewart A Low
Journal:  Curr Osteoporos Rep       Date:  2020-10       Impact factor: 5.096

8.  Rapid cell culture and pre-clinical screening of a transforming growth factor-beta (TGF-beta) inhibitor for orthopaedics.

Authors:  Aaron Schindeler; Alyson Morse; Lauren Peacock; Kathy Mikulec; Nicole Y C Yu; Renjing Liu; Sandy Kijumnuayporn; Michelle M McDonald; Paul A Baldock; Andrew J Ruys; David G Little
Journal:  BMC Musculoskelet Disord       Date:  2010-05-28       Impact factor: 2.362

Review 9.  Avascular Necrosis of the Femoral Head: Are Any Genes Involved?

Authors:  Farzaneh Pouya; Mohammad Amin Kerachian
Journal:  Arch Bone Jt Surg       Date:  2015-07

10.  Injectable chitosan microparticles incorporating bone morphogenetic protein-7 for bone tissue regeneration.

Authors:  Venkata P Mantripragada; Ambalangodage C Jayasuriya
Journal:  J Biomed Mater Res A       Date:  2014-02-14       Impact factor: 4.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.